Cilgavimab
Based on 1 publication(s) in Google Scholar
Cilgavimab (AZD-1061; COV2-2130) is a human SARS-CoV-2-neutralizing monoclonal antibody, can compose monoclonal-antibody combination AZD7442 with Tixagevimab (HY-P99556). Cilgavimab shows protective action on mouse models of SARS-CoV-2 infection.
For research use only. We do not sell to patients.
- Purity : 95.00%
- CAS No.: 2420563-99-9
- Molecular Weight:148.82 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
Severe acute respiratory syndrome coronavirus 2
In Vitro
Cilgavimab and Tixagevimab simultaneously bind to distinct, nonoverlapping epitopes of the SARS-CoV-2 spike-protein (S) receptor-binding domain to potently neutralize the virus[1].
Cilgavimab exhibits potent monoclonal antibody neutralization activity, and human ACE2-blocking activity, with IC50s of 10-150 ng/mL, and shows binding ability to either trimeric S2Pecto protein or monomeric SRBD with IC50s of 0.1-10 ng/mL[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Product Details
-
CAS No. 2420563-99-9
-
Accession P59594
-
Gene ID 43740600 [NCBI]
-
Synonyms AZD-1061; COV2-2130
-
Molecular Weight 148.82 kDa
-
Species Reactivity
Virus
-
Conjugated
Unconjugated
-
Isotype
Human IgG1 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG1 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
95.00%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Shipping
Shipping with dry ice.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Emerg Microbes Infect
Deep mutational scanning reveals the antibody escape and infectivity landscape of SARS-CoV-2 Omicron JN.1 and XEC receptor-binding domains. [Abstract]2026 Dec;15(1):2686472. PMID: 42324717
Purity & Documentation
References
[1]. Levin MJ, et al; PROVENT Study Group. Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. N Engl J Med. 2022 Jun 9;386(23):2188-2200. [Content Brief]
[2]. Zost SJ, et al. Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature. 2020 Aug;584(7821):443-449. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)